Most brain cells turn out to be generalists, not specialists

Biotech & Longevity 4 min 80 sources

A new study finds the brain runs on jack-of-all-trades neurons, not a roster of experts - plus an FDA panel waves through unproven peptides, Lilly's next weight-loss drug, measles at a 35-year high, and a death in a Chinese gene-editing trial.

Key takeaways

A new mouse study suggests the brain's abilities live in crowds of general-purpose neurons, not in a filing cabinet of specialist cells.
An FDA advisory panel recommended broad access to six largely unproven peptides, including the online favourite BPC-157, over its own scientists' safety concerns.
US measles cases hit a 35-year high at 2,318, while a death in a Chinese gene-editing trial and CAR-T safety flags show how young these tools still are.

The brain’s real workforce is the crowd, not the stars

For decades, neuroscience has collected star neurons. There are place cells that fire only at a particular spot in a room. And there is the famous “Jennifer Aniston cell,” which lit up for one celebrity and stayed quiet for almost everything else [22]. That gave us a tidy picture: the brain as a filing cabinet of specialist cells, one job each.

A new study in mice says that picture is mostly wrong [22]. When researchers looked at large populations of neurons rather than hunting for the standout ones, most cells turned out to be generalists. Each fires a little for many different things, not one thing cleanly. “These neurons are really the exception, not the rule,” says Stefano Fusi of Columbia University, meaning the tidy specialists we kept finding [22]. The unglamorous, mixed-response cells, he argues, may matter as much or more.

The caveat is real: this is one study, in mice, and it does not overturn that some genuine specialists exist. But it lands a bigger idea. The brain’s abilities may not sit inside individual expert cells at all. They may live in the pattern across thousands of ordinary ones.

An FDA panel opens the door to unproven peptides

Advisers to the FDA, the US drug regulator, spent two days this week recommending broader access to a set of peptides [43]. Peptides are short chains of amino acids, sold widely online but never approved as drugs. The panel voted to let compounding pharmacies make six of the seven under review for patients with a prescription [43]. Among them is BPC-157, a gym-and-wellness favourite with almost no human trial data [56].

The vote reverses restrictions from the previous administration and aligns with Health Secretary Robert F. Kennedy Jr. [43]. The FDA’s own scientists had flagged thin evidence on safety and effectiveness [46]. A recommendation is not yet a rule - the agency still decides - but it signals a real loosening of the line between a supplement and a medicine [74].

Lilly’s next weight-loss drug lands, a step short

Eli Lilly said its “triple-G” drug retatrutide hit the main goals of two late-stage trials, with patients losing 22.6% of their body weight [28]. That is a large number. It is also below the peak seen in earlier retatrutide trials [28]. And its effect on cutting heart attacks and strokes - the thing that ultimately matters - is still unclear. A “phase 3” trial is the big final test before approval, comparing a drug against a dummy pill in hundreds or thousands of people.

Old diseases, new numbers

The US recorded 2,318 measles cases this year, the most since the 1989-to-1991 resurgence - a 35-year high, driven by falling vaccination rates [76]. Measles was declared eliminated in the country in 2000; it is contagious enough that even small dips in coverage let it return.

Better news elsewhere: India approved Takeda’s Qdenga, its first dengue vaccine, against a mosquito-borne virus that sickens millions there each year [53].

Two reminders that the tools are still young

A patient died in a gene-editing trial in China, prompting questions about ethics and oversight in a field racing ahead [63]. Details are still emerging, but the death is a hard reminder that rewriting DNA in a living person carries real risk, not just promise.

On the safer side of the same technology, there was progress. An analysis of patients treated with Kite’s CAR-T cancer therapy Yescarta found genetic signatures that flag who is most at risk of severe side effects [13]. CAR-T re-engineers a patient’s own immune cells to hunt cancer; knowing in advance who is at risk could make it safer to use.

The machines move into the lab

AI kept threading through the week. Researchers used a system built on AlphaFold3, the protein-structure model, to design more precise DNA base editors [27]. A separate team used AI to redesign the starting points for evolving new proteins, raising the hit rate [44]. Bristol Myers Squibb tied up with Nvidia to build what it called a large “AI factory” for drug research [37]. And lab-grown “mini-brains” - pinhead clusters of a patient’s own brain cells - were used to predict which Alzheimer’s treatments a given person might respond to [14].

The bugs we can’t see one at a time

Finally, the week’s quiet thread was the microbiome - the vast community of microbes living in and around us. Scientists are testing whether adjusting gut bacteria could ease depression and anxiety, a field that drew open scepticism a decade ago [1]. And in the largest survey of its kind, researchers mapped the Great Barrier Reef’s microbes, finding more than 500 bacterial species new to science and over 360,000 viruses [41]. No single microbe runs a gut or a reef. What keeps either alive is the whole community, working together.

02 · Lesson · why it matters

Why you can't find a thought by holding one brain cell up to the light

The most important thing a system does often lives in no single part - only in how the parts act together.

The hunt for the cell that knows

For decades, brain scientists went looking for the cell that holds the answer. They found place cells that fire only when you stand in one corner of a room. They found a neuron that lit up for photographs of one actor and stayed quiet for almost everything else. Each discovery felt like opening a drawer and finding a label inside: this cell means here, that cell means her. The brain looked like a filing cabinet of experts, one fact per cell.

This week a study in mice suggested the filing cabinet is mostly empty. When researchers stopped hunting for standout cells and looked at whole crowds of neurons, most turned out to be generalists. Each fires a little for many things, none cleanly “about” one. The clean specialists, one scientist said, are the exception, not the rule. The workers doing the job are the vague, mixed-up majority.

The wetness problem

Here is the idea underneath. Take a single molecule of water and ask it: are you wet? The question makes no sense. Wetness is not a property a molecule has. It appears only when trillions of them slide past each other. You will never find it by studying one, however powerful your microscope.

This is called emergence. A whole can do things that none of its parts can do, and that you cannot read off any part. The behaviour does not live in the pieces. It lives in how the pieces act together. A thought is not in a neuron any more than wetness is in a molecule. It is in the pattern across many.

Why we keep looking in the wrong place

We miss this again and again, and it is not carelessness. It is method. The way you find a specialist cell is to record from cells one at a time and keep the striking ones. That technique is beautiful at finding stars and blind to crowds. It made the specialists visible and the generalists invisible - not because the generalists were rare, but because the tool wasn’t built to see them.

So the map we drew was shaped by how we searched. The parts that stood out on their own became the story. The parts that only mean something together - the majority - dropped out of the picture. What looked like a full account of the brain was really an account of its most photogenic cells.

The same shape, everywhere you look

Once you see emergence, you see it running through the week’s other news. Scientists are testing whether shifting the mix of bacteria in your gut can ease depression. Notice what they are not claiming: that one microbe is the sadness bug. No single species runs your gut. Mood, digestion, immunity - these come out of a whole community trading chemicals, and you cannot bottle the effect by naming one member.

Researchers also mapped the microbes of the Great Barrier Reef and found more than five hundred bacterial species new to science. No one of them keeps the reef alive. The reef’s health is a thing the whole community does, and does invisibly, until enough of it is gone. A market price is like this too. It sits in no single trader’s head. So is a traffic jam, which is in no single car. So is a language, which is in no single speaker.

The part you can’t step outside

Here is where it comes home. You are not standing outside these systems, studying them. You are one.

Your sense of being a single, continuous “you” is not stored in a “you” cell. There is no neuron that knows your name, holds your childhood, decides your next move. That felt-solid self is what happens when billions of ordinary, generalist cells act together - the same kind of crowd, doing the same kind of trick. Cut the brain into its parts and the self is not in any of them. It is the wetness of that particular water.

This is worth holding loosely. It means you can’t fully understand a mind, a gut, a reef, a market, or a society by pulling out one part and asking what it does. The answer was never in there. And it means the thing asking the question is itself one of these wholes, made of pieces that don’t know what they add up to. We are very good at finding the star, labelling the drawer, and mistaking it for the room. Most of what matters was in the crowd the whole time, doing quietly together what nothing in it could do alone.

03 · Lab · your turn

Find the cell that knows

Probe one neuron and it only guesses; read the whole population and the answer appears. Rehearse how a system's ability lives in the crowd, not any part.

04 · Hope · carry this

A thought, a healthy gut, a living reef, a steady self - none is the work of any single part. Each is what ordinary things become when they act together, which is quietly one of the most hopeful facts we know.